Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More good news!
Radient Technologies Inc. and Fluum Inc. Enter Into Multi-Year White Label Deal
https://web.tmxmoney.com/article.php?newsid=5188957150255523&qm_symbol=RTI
Hell yes about time, glad I loaded more at these levels.
I’ve been waiting for so long!
https://finance.yahoo.com/news/radient-technologies-inc-announces-receipt-113010822.html
Full Steam Ahead At Cannabis Extractor Radient Technologies
May 27, 2020 2:05 PM ETRadient Technologies Inc (RDDTF)ACB, MEDIF, VLNCF24 Comments
Summary
Cannabis extraction is the future of the industry.
Radient Technologies has a superior extraction technology.
Their throughput and economies of scale will make them a leader in the extraction industry.
Extracts are the Future
The future of cannabis is undoubtedly one that leans toward cannabis derivatives, such as vaporizers, edibles and topicals. With derivatives anticipated to account for roughly half the multi-billion dollar cannabis market, the cannabis extracts that go into them are in high demand.
An entire industry is cropping up around cannabis extraction. Some companies are marketing their cannabis extraction machines to cannabis producers, for onsite extraction. Other companies have built out large extraction facilities with the intent to either extract cannabis for a processing fee (extraction as a service) or to buy cannabis on the open market and manufacture their own cannabis derivatives for sale to cannabis retailers (white label). Radient Technologies Inc. (CSE: RTI) is one such company that believes they have a unique advantage that will allow them to become the industry leader.
A Superior Extractor
Radient’s claim to fame is its use of Microwave Assisted Processing (MAP) to aid in their extraction efforts. MAP heats the cannabis biomass to precise temperatures for exact periods of time, allowing for a higher quality product. The technology also uses less solvent than the methods being used by other companies and has higher throughput, allowing for improved economies of scale.
Independent lab results have shown Radient’s extraction process preserved up to 99% of desired cannabinoids, while other extractors capture 70-80%. MAP also gives Radient better control to select for specific compounds, allowing them to better customize their product to meet customer needs. Unlike many other extraction technologies, MAP is also well suited for extracting CBD from hemp. This allows Radient to serve a wider variety of clients and produce a greater number of their own products.
Extraction is a Go
Despite being in existence for over twenty years, Radient only recently got into the cannabis industry. In 2017, the company signed an agreement with leading cannabis producer Aurora Cannabis (NYSE: ACB) to provide extraction as a service. They then set about building out extensive facilities with large throughput near Aurora’s Edmonton Sky facility, one of the largest and most advanced cannabis growing facilities in the world.
Since getting their first facility licensed last year, Radient has generated over $20 million in revenues from their Aurora partnership. After spending the year optimizing their production line, the company began to sign deals with additional partners.
Earlier this year the company announced a three-way extraction as a service deal with Allied Corp and the Dhaliwal Group. Allied will supply cannabis biomass to Radient for extraction and the resulting product will then be distributed to cannabis retailers by the Dhaliwal Group. A part of the deal allows Radient to accept biomass in lieu of cash. This gives the company the ability to acquire biomass at below market rates that they can then process into their white label products, boosting profit margins.
Radient’s first white label deal is with Cannabis by Shoppers Drug Mart. Radient will supply high quality medical cannabis products and Shoppers will sell them under exclusive in-house brands. The first brand is bioU and the first product is a high THC oral spray.
Most recently, Radient announced an initiative to study the possibility of using their cannabis extracts to prevent and/or treat COVID-19. Radient will partner with two other companies to develop proprietary formulations, run patient studies and potentially file a patent. If successful, this could put Radient into the global conversation and provide a huge boost to the company’s revenues.
Competing Extractors
There are two companies currently leading the extraction industry: MediPharm Labs (OTCQX:MEDIF) and the Valens Company (OTCQX:VLNCF). Both of these companies have been in operation for the last year or more and have established substantial partnerships with several major cannabis producers.
While both MediPharm Labs and the Valens Company engage in extraction and a service and white label manufacturing, they differ in their chose extraction processes. MediPharm primarily uses Supercritical CO2 extraction, while Valens incorporates ethanol, hydrocarbon and solvent-less extraction technologies.
Each different technology is best-suited for producing a certain type of extract. Radient’s MAP gives them such precise control over their extraction that they are able to create a wider variety of products than any other extraction technology
Both MediPharm and Valens are ahead of Radient in terms of business development. They’ve been partnering with some of the largest Canadian cannabis producers, including Canopy Growth, Tilray, Hexo and Organigram. MediPharm has gone so far as to establish overseas operations in Australia. Already shipping finished product, the company is also in the process of building a local manufacturing facility.
Radient is rapidly catching up to the industry leaders. The company has finished 2 of their 3 planned Canadian facilities, with the 2nd receiving its license earlier this year. Construction is ongoing on their 3rd and largest facility, which should be completed later this year and in production in 2021. This facility should give Radient the highest throughput in Canada. Also under construction is a similar facility in Germany, where demand is expected to explode over the coming years.
2021 should see Radient with the highest throughput in both North America and Europe.
Full Steam Ahead At Cannabis Extractor Radient Technologies
May 27, 2020 2:05 PM ETRadient Technologies Inc (RDDTF)ACB, MEDIF, VLNCF24 Comments
Summary
Cannabis extraction is the future of the industry.
Radient Technologies has a superior extraction technology.
Their throughput and economies of scale will make them a leader in the extraction industry.
Extracts are the Future
The future of cannabis is undoubtedly one that leans toward cannabis derivatives, such as vaporizers, edibles and topicals. With derivatives anticipated to account for roughly half the multi-billion dollar cannabis market, the cannabis extracts that go into them are in high demand.
An entire industry is cropping up around cannabis extraction. Some companies are marketing their cannabis extraction machines to cannabis producers, for onsite extraction. Other companies have built out large extraction facilities with the intent to either extract cannabis for a processing fee (extraction as a service) or to buy cannabis on the open market and manufacture their own cannabis derivatives for sale to cannabis retailers (white label). Radient Technologies Inc. (CSE: RTI) is one such company that believes they have a unique advantage that will allow them to become the industry leader.
A Superior Extractor
Radient’s claim to fame is its use of Microwave Assisted Processing (MAP) to aid in their extraction efforts. MAP heats the cannabis biomass to precise temperatures for exact periods of time, allowing for a higher quality product. The technology also uses less solvent than the methods being used by other companies and has higher throughput, allowing for improved economies of scale.
Independent lab results have shown Radient’s extraction process preserved up to 99% of desired cannabinoids, while other extractors capture 70-80%. MAP also gives Radient better control to select for specific compounds, allowing them to better customize their product to meet customer needs. Unlike many other extraction technologies, MAP is also well suited for extracting CBD from hemp. This allows Radient to serve a wider variety of clients and produce a greater number of their own products.
Extraction is a Go
Despite being in existence for over twenty years, Radient only recently got into the cannabis industry. In 2017, the company signed an agreement with leading cannabis producer Aurora Cannabis (NYSE: ACB) to provide extraction as a service. They then set about building out extensive facilities with large throughput near Aurora’s Edmonton Sky facility, one of the largest and most advanced cannabis growing facilities in the world.
Since getting their first facility licensed last year, Radient has generated over $20 million in revenues from their Aurora partnership. After spending the year optimizing their production line, the company began to sign deals with additional partners.
Earlier this year the company announced a three-way extraction as a service deal with Allied Corp and the Dhaliwal Group. Allied will supply cannabis biomass to Radient for extraction and the resulting product will then be distributed to cannabis retailers by the Dhaliwal Group. A part of the deal allows Radient to accept biomass in lieu of cash. This gives the company the ability to acquire biomass at below market rates that they can then process into their white label products, boosting profit margins.
Radient’s first white label deal is with Cannabis by Shoppers Drug Mart. Radient will supply high quality medical cannabis products and Shoppers will sell them under exclusive in-house brands. The first brand is bioU and the first product is a high THC oral spray.
Most recently, Radient announced an initiative to study the possibility of using their cannabis extracts to prevent and/or treat COVID-19. Radient will partner with two other companies to develop proprietary formulations, run patient studies and potentially file a patent. If successful, this could put Radient into the global conversation and provide a huge boost to the company’s revenues.
Competing Extractors
There are two companies currently leading the extraction industry: MediPharm Labs (OTCQX:MEDIF) and the Valens Company (OTCQX:VLNCF). Both of these companies have been in operation for the last year or more and have established substantial partnerships with several major cannabis producers.
While both MediPharm Labs and the Valens Company engage in extraction and a service and white label manufacturing, they differ in their chose extraction processes. MediPharm primarily uses Supercritical CO2 extraction, while Valens incorporates ethanol, hydrocarbon and solvent-less extraction technologies.
Each different technology is best-suited for producing a certain type of extract. Radient’s MAP gives them such precise control over their extraction that they are able to create a wider variety of products than any other extraction technology
Both MediPharm and Valens are ahead of Radient in terms of business development. They’ve been partnering with some of the largest Canadian cannabis producers, including Canopy Growth, Tilray, Hexo and Organigram. MediPharm has gone so far as to establish overseas operations in Australia. Already shipping finished product, the company is also in the process of building a local manufacturing facility.
Radient is rapidly catching up to the industry leaders. The company has finished 2 of their 3 planned Canadian facilities, with the 2nd receiving its license earlier this year. Construction is ongoing on their 3rd and largest facility, which should be completed later this year and in production in 2021. This facility should give Radient the highest throughput in Canada. Also under construction is a similar facility in Germany, where demand is expected to explode over the coming years.
2021 should see Radient with the highest throughput in both North America and Europe, the two largest cannabis markets in the world. Coupled with their ability to deliver a high quality product at a low price point, Radient stands to overtake Valens and MediPharm as the leader in cannabis extraction.
(2)
gymhog
Me too, loonng time.
Reply
Like
(1)
https://web.tmxmoney.com/article.php?newsid=6726374490727895&qm_symbol=RTI
Radient Announces Successful Closing of its Equity Offering for Gross Proceeds of $5,750,000
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
EDMONTON, Alberta, May 26, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has closed its public equity financing initially announced on May 20, 2020. The Company issued 28,750,000 units (the “Units”) of the Company (which includes 3,750,000 Units issued pursuant to the exercise in full of the over-allotment option) at a price of $0.20 per Unit (the “Offering Price”) for aggregate gross proceeds of $5,750,000 (the “Offering”). The Offering was completed by Eight Capital (the “Agent”) as sole agent.
Each Unit consisted of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share, at an exercise price of $0.30 until May 26, 2023. The Warrants will not be listed for trading on the TSX Venture Exchange or any other public exchange.
In connection with the Offering the Company has paid the Agent a cash fee equal to up to 7% of the aggregate proceeds from the Offering (the “Commission”). In addition to the Commission, the Company has issued to the Agent non-transferable compensation warrants equal to up to 7% of the Units sold under the Offering. Each compensation warrant is exercisable for a Unit at the Offering Price until May 26, 2023.
The net proceeds of the Offering will be used for working capital and general corporate purposes as set out in the Prospectus Supplement (as defined below).
The Offering was conducted in Canada pursuant to a prospectus supplement dated May 21, 2020 (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus, filed in all of the provinces of Canada except for Québec, and offered outside of Canada on a private placement basis.
Certain management and insiders of the Company participated in the Offering and were issued an aggregate of 425,000 Units. Such participation in the Offering constitutes a “related party transaction” as defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Offering is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities issued to related parties nor the consideration for such securities exceed 25% of the Company’s market capitalization. The Company did not file a material change report 21 days prior to closing of the Offering as the participation of insiders of the Company in the Offering had not been confirmed at that time.
The Offering remains subject to the final approval of the TSXV.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state of the United States in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as such terms are defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements of the 1933 Act and any applicable state securities laws.
Radient Technologies Inc. Launches bioU, a Brand of High Quality Cannabis Extract Formulations Exclusively for Medical Cannabis by Shoppers
EDMONTON, Alberta, May 21, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global manufacturer of high quality cannabinoid-based ingredients, formulations and products, is pleased to announce the launch of bioU, a scientifically formulated brand exclusively sold to Medical Cannabis by Shoppers™ (“Shoppers”), a subsidiary of Shoppers Drug Mart Inc., and available across Canada.
Radient’s first products released under the bioU label will be the Uspray series of high quality, scientifically formulated oral cannabis sprays. bioU Uspray will have three formulations available to consumers on the Medical Cannabis by Shoppers online platform; a THC dominant formula with 30mg/mL of THC and 1 mg/mL of CBD, a CBD dominant formula with 20 mg/mL CBD and 1 mg/mL THC, and a balanced formula with 10 mg/mL THC and 10 mg/mL CBD. All bioU products have been designed by Radient to retain cannabinoids and terpenes while providing high levels of purity and consistency.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a47c568-48b7-40b2-ad40-cb7d1a08b2a9
“We are very excited to launch this line of products with Medical Cannabis by Shoppers. This is a key step for the Company in forging a long-term and successful partnership with one of Canada’s most trusted names in retail. We look forward to broadening our product offering with Shoppers and giving consumers access to the first branded products from Radient,” said Denis Taschuk, Chief Executive Officer, Radient Technologies.
Radient plans on expanding the products available under the bioU brand over the coming months. The bioU brand will use Radient’s proprietary broad spectrum cannabinoid extracts along with an extensive library of internally developed formulations. Radient’s unique, continuous-flow extraction process has been proven to achieve a higher recovery of active compounds from the cannabis plant (up to 99%) than other extraction methods. It has lower risk of cannabinoid degradation during processing which allows products to maintain shelf life for a longer period of time, and has a high level of product consistency. Combining its unique extraction technology with stringent quality control systems and decades of botanical ingredient manufacturing experience, Radient produces a variety of broad spectrum cannabinoid formulations, ingredients and products that meet the highest standards of quality and safety.
https://web.tmxmoney.com/article.php?newsid=7390427121225451&qm_symbol=RTI
Radient Technologies Announces $5 Million Equity Offering
EDMONTON, Alberta, May 20, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce a proposed offering of 25,000,000 units (the “Units”) at an offering price of $0.20 per Unit (the “Issue Price”), for aggregate gross proceeds of up to $5,000,000 (the “Offering”). The Units will be offered on a best efforts basis by Eight Capital, as agent for the Company (the “Agent”), pursuant to a prospectus supplement to Radient’s base shelf prospectus dated January 21, 2020 (collectively, the “Prospectus”). BDO Canada LLP is acting as Radient’s financial advisor in connection with the Offering.
Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share, at an exercise price of $0.30, for a period of 36 months following the closing of the Offering.
The Company has agreed to grant the Agents an over-allotment option (the “Over-Allotment Option”) to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, the Company will receive an additional $750,000 in gross proceeds for total aggregate gross proceeds of $5,750,000.
In connection with the Offering the Company has agreed to pay the Agent a cash fee of 7% of the aggregate gross proceeds raised from the Offering, and non-transferable compensation warrants (“Compensation Warrants”) equal to 7% of the Units sold under the Offering (in each case including any exercise of the Over-Allotment Option). Each Compensation Warrant will be exercisable into one Unit at the Issue Price for a period of 36 months following closing.
The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes.
The closing date of the Offering is scheduled to be on or about May 26, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
About Radient
Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.
https://web.tmxmoney.com/article.php?newsid=8871277112339930&qm_symbol=RTI
ORIGINAL: Radient Technologies Inc. Announces Collaboration on the Development of Anti-Viral Products and Files Patent Application Covering Cannabinoid Based Compositions for the Mitigation and Protection from Viruses
2020-05-19 07:00 ET - News Release
EDMONTON, Alberta, May 19, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces that it has filed a provisional patent application covering the use of a combination of cannabinoids, terpenes and zinc (the “Formulations”) as a means of preventing infection of coronavirus, mitigating the symptoms of coronavirus, and lowering infectiousness of Covid-19 patients, with the goal of reducing hospitalizations and intensive care unit requirements. Additionally, the Company announces that it will lead a collaboration with two US based groups, IntuitiveX (“IntuitiveX”) and ipCapital Group (“ipCapital”), to explore the development of new anti-viral products using the Formulations.
The Company is not making any express or implied claims as to the effectiveness of the Formulations or its ability to mitigate the symptoms of, eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus), and there can be no assurance that the Formulations will be effective or reach commercial production. The Company plans to collaborate with IntuitiveX and ipCapital to develop a process and timeline for the development of the Formulations.
Patent Application
The Company has filed a provisional patent application with the US Patent and Trademark Office (“USPTO”) that covers the Formulations as a means of preventing infection of, mitigating the symptoms of, and lowering infectiousness of viral respiratory infections, including Covid-19, in patients.
“Filing this patent application with the USPTO gives us an international priority date that will allow us to nationalize in other selected jurisdictions in the future, including, for example, Canada, Europe and Asia,” said Dr. Steven Splinter, Chief Technology Officer of Radient.
Collaboration
The Company announced that it will be collaborating with ipCapital, IntuitiveX and a third party contract research organization to be determined with a goal of developing, clinically testing and marketing cannabinoid based products that are targeted at lessening and/or eliminating the effects of Covid-19 in patients.
“We are excited to announce this important initiative, which brings together our team of experienced research scientists along with scientific, regulatory and technology expertise that each of these groups possess. We believe this collaboration will greatly assist with the development pathway for the Formulations,” said Denis Taschuk, Chief Executive Officer of Radient.
The Company, ipCapital and their advisors have done a review of existing scientific literature that has focused on the use of cannabinoids and/or zinc compounds for anti-inflammatory and anti-viral indications. The Company believes there is sufficient scientific evidence from its review to support exploring the efficacy of the Formulations. As previous research work has been done by other groups on the use of cannabinoids or zinc for anti-viral purposes, the Company will be looking to validate that work through its own efforts with the specific viral target for this project. It is expected that Radient’s dedicated innovation laboratory will lead the product development and the Company’s proprietary processing technology will be used to produce the high-purity cannabinoids required for this product.
Dr. Anna Bakowska-Barczak, Director of Formulations and Product Development at Radient will oversee the formulation development for patient studies. She has over 15 years of process/product development, formulation, and regulatory experience. She currently leads Radient’s formulation and product development team and has developed and continues to develop a broad range of proprietary cannabinoid-based product formulations for both medical and consumer markets. Dr. Bakowska-Barczak is a recognized expert in formulation and product development for food and nutraceutical markets, including cannabis. She holds Engineering and Master Degrees in Food Science and received her Ph.D. in Food Science in 2005. She has authored or co-authored over 30 peer-reviewed scientific publications and is the inventor of 13 patent applications.
The Company has developed significant cannabinoid expertise as a result of its research efforts of the last three years. During this time the Company built up its scientific team to include over 25 in house scientists and engineers and has invested over $5 million on its research, process development and intellectual property portfolio. The Company has developed, during this time, a number of proprietary formulations that it hopes will form the base of the development of a final formulation(s) for this Covid-19 program. As well, the Company believes that it has the necessary equipment to develop and manufacture the necessary product formulations for patient studies including analytical testing of the composition of the formulations.
IntuitiveX, a Seattle, Washington based life sciences advisory firm that has a long work-ing history with ipCapital, and is closely associated with one of Seattle’s leading hospitals, will act as a service provider. It will lead the efforts associated with testing, regulatory approvals and additionally, incorporate their advanced monitoring capabilities allowing for rapid collection and evaluation of data.
ipCapital Group, a leading Intellectual Property(“IP”) consulting firm, based in Williston, Vermont, has been assisting the Company with its IP strategy for two years and will lead the IP and innovation strategy for the project.
“We are happy to be part of this collaboration to advise on the IP strategy and the IP development,” says John Cronin, Managing Director of ipCapital. Together, the three companies, and through their networks, have strong product development, clinical and regulatory expertise. Additionally, the Company expects to support its patient study activities by adding a third party contract research organization to assist in the design, execution and evaluation of results of patient studies required.
The group will be working to develop new anti-viral products, initially targeted at Covid-19, that the group hopes will provide mitigation in the form of reduction of symptoms leading to fewer hospitalizations and reduced ICU requirements. “Our goal is to combine two over-the-counter anti-inflammatory/anti-viral mitigators that are already well appreciated in research: cannabinoids and zinc,” said Dr. Splinter. “There is a body of evidence that cannabinoids and their receptors influence viral pathogenesis, viral replication and of course the immune system itself. Further, other research has shown the inhibitory effect of zinc on viruses that attack the respiratory tract, including for example rhinovirus. We believe that the combination could potentially be an effective anti-viral treatment.”
The Company envisions starting patient studies with residents of long term care facilities, currently expected to be in the Seattle, Washington area, in order to test the efficacy of the Formulations both on high risk staff as well as nursing home patients. Radient is also considering exploring the use of the Formulations to mitigate ongoing symptoms of certain post Covid-19 survivors, notably those with continued pulmonary fibrotic disease. No such patient studies have been scheduled as of yet, and there is no certainty that any such patient studies will be scheduled.
Key milestones for the project would include 1) completion of final formulations including dosing determination, 2) patient study design including identification of test sites and study leaders, 3) regulatory approval of study and 4) execution of study with evaluation of results.
About Radient
Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.
About IntuitiveX
IntuitiveX is a life science consultancy and incubator created to help entrepreneurs and startups transform their ideas from concept to commercialization. IntuitiveX has a team of business, legal, clinical, scientific and intellectual property domain experts with over 50+ years of combined experience who provide a full spectrum of services to entrepreneurs and startups.
About ipCapital
ipCapital, celebrating 22 years in business, with over 1000 clients, serving >15% of the F500 and hundreds of medium and small businesses using its interdisciplinary team of consultants and advisors and programmers who are all focused on maximizing clients’ financial results. ipCapital combines its world-class human capital with its proprietary AI based tools and methodologies around innovation, invention, and Intellectual Property.
SOURCE: Radient Technologies Inc.
Contact for Radient: Investor Relations: ir@radientinc.com
Contact for Intuitive-X: Simon Robinson: srobinson@intuitive-x.com
And here it is the news
https://web.tmxmoney.com/article.php?newsid=7881372603633509&qm_symbol=RTI
I just found this and I bet Radient extracts the CBD for Aurora
https://www.roarsports.com
I think the other one is spliff
Apparently 2 other companies halted at the same time? BUZZ something or other and a related company... Hope it’s something decent! Gotta move this Radient needle.
Could not find any reason for the trading halt myself. ANYONE have any info ????
Nothing that I have seen. It was on the rise when it halted up .06 in Canada if that means anything at all
I am keeping track of about 25 Cannabis stocks and have positions in
four right now.
EMERALD
WEEDMD
SUPREME
KHIRON
I am keeping track of about 5 Mushroom stocks and have a position in
one right now
MINDMED
New board Magic Mushroom Stocks
What made you decide to look at Radient was it something in the chart?
Looking close at Radiant here. I have picked up a few cannabis companies off the floor.
Discussion board Cannabis Investment Club
This smells like a Terry Booth move
Well that sucks another loss for me
I bought a few days ago I don’t have any buy orders in
See If you can cancel your buy before the halt lifts
Its Bad News...More dilution
Radient arranges $9.4-million at-the-market program
2020-03-27 12:29 ET - News Release
Mr. Prakash Hariharan reports
RADIENT ANNOUNCES THE INITIATION OF AN AT-THE-MARKET EQUITY PROGRAM AND PROVIDES AN UPDATE ON INITIATIVES TO MEET CUSTOMER DEMAND DURING COVID-19 PANDEMIC, FINANCING ACTIVITIES AND LIQUIDITY
Radient Technologies Inc. has established an at-the-market equity program. The Company also announces that it is actively reviewing its operations in response to guidance from governmental and health authorities with a view to limiting the spread of the virus that causes COVID-19, and also wishes to provide an update on its current liquidity and financing activities.
ATM Program
The ATM Program will allow the Company to issue up to $9.4 million worth of common shares from treasury ("Common Shares") to the public from time to time at prevailing market prices through the TSX Venture Exchange ("TSXV") or any other marketplace on which the Common Shares are listed, quoted or otherwise traded in Canada. The volume and timing of distributions under the ATM Program, if any, will be determined at the Company's sole discretion, subject to applicable regulatory limitations.
Sales of Common Shares through the ATM Program will be made pursuant to National Instrument 44-102 Shelf Distributions and the terms of an equity distribution agreement dated March 26, 2020 entered into between the Company and National Bank Financial Inc. (the "Agent"), as agent. The ATM Program will be effective until February 21, 2022, unless all Common Shares available for issue under the ATM Program have been issued or the ATM Program is terminated prior to such date by the Company or the Agent.
Radient intends to use the net proceeds from the ATM Program, if any, for funding:
additional equipment for the Company's Edmonton I facility to allow for faster stream time as well as allowing an increase in evaporation capacity increasing Radient's product pipeline;
additional refining equipment, refurbishing existing equipment facility space and designing and installing customized downstream equipment for the Company's Edmonton II facility;
capital investment in further cannabinoid extraction, purification, isolation and product manufacturing capabilities at the Company's Edmonton III facility;
the Company's planned project in Germany, similar to the Company's Edmonton III facility, to deliver consistent cannabinoid derivatives and formulations, manufactured in accordance with EU GMP requirements; and
general corporate purposes.
The Company has filed a prospectus supplement dated March 26, 2020 ("Prospectus Supplement") to its base shelf prospectus dated January 21, 2020 ("Base Shelf Prospectus") with each of the securities regulatory authorities in each of the provinces of Canada for the initiation of the ATM Program. Before you invest, you should read the Company's Prospectus Supplement, the Base Shelf Prospectus, and all other documents the Company has filed with the Canadian securities regulatory authorities for more complete information about the Company and the ATM Program. These documents may be downloaded from SEDAR at www.sedar.com. Alternatively, the Agent will arrange to send you these documents if you request it by contacting:
NBF Syndication, 130 King Street West, 4th Floor Podium, Toronto, Ontario, M5X 1J9, or by telephone at (416)-869-6534, or by email at ecm@nbf.ca.
Operational Update
In response to the COVID-19 pandemic, the Company's workforce will be reduced due to temporary layoffs, effectively retaining only those staff who the Company believes are essential to maintaining the safety of day-to-day operations. The Company plans to reorganise its workforce, focus on current projects at hand and utilize existing inventory to process cannabinoid extracts including resins, distillates and isolates.
The Company has also instituted additional COVID-19 measures, including:
essential staff who are able to work from home have been asked to do so;
all staff have been instructed to practice social distancing;
expanded hygiene and cleaning protocols have been implemented at all sites;
access to all sites is restricted to essential personnel; and
additional preventive measures in operating activities have been implemented that will ensure the highest level of safety in the products we produce for our customers.
"In these challenging times we are committed to continuing to deliver high-quality products to our customers, while maintaining the strictest level of safety for our employees," said Denis Taschuk, President and CEO of Radient.
Despite current economic conditions, the Company believes there is strong consumer demand for cannabis-based products, both medical and recreational. The temporary layoffs announced today are expected to allow the Company to quickly recall workers and safely scale up operations, as required to meet customer demand.
By managing its resources in this fashion while leveraging its proprietary product development platform, Radient expects to execute on its current commitments, such as its recently executed manufacturing agreements with Allied Corp., Dhaliwal Group and Shoppers Drug Mart, and any other near-term opportunities, while maintaining the highest standards of safety and quality for its products which include THC and CBD-based oils, resins, distillates and isolates. Other aspects of Radient's business, including deliveries of finished products, will not be impacted by these staffing measures.
"These measures will allow Radient to manage its capital and human resources to respond to any increase in demand, while ensuring a safe work environment," said Taschuk. "We are continuing to attract positive responses from potential customers in our pursuit of additional opportunities."
Financing and Liquidity Update
In addition to the initiation of the ATM Program, the Company also wishes to provide an update on its current liquidity and financing activities. As of the date hereof, the Company has net working capital of $2.75 million exclusive of an account payable in respect of the Edmonton III facility in the amount of $7.1 million. Radient continues to pursue financing, including the following previously announced initiatives:
Debenture Financing
The Company announced a debenture financing of up to $5,000,000 on February 10, 2020. The Company announced the closing of the first tranche of debentures on March 4, 2020 for gross proceeds of CAD$1,162,500. The Company continues to pursue completion of the full $5,000,000 debenture financing.
Note Financing
The Company announced that it entered into a non-binding letter of intent with an institutional investor with respect to a proposed note financing on February 10, 2020 for gross proceeds of up to $10.4 million. Due diligence by the institutional investor is now substantially complete and the financing remains subject to execution of definitive documentation and regulatory approval, including approval of the TSXV.
Sale and Leaseback
The Company announced on January 14, 2020 that it entered into a binding letter of intent with 223801 Alberta Ltd (the "Purchaser") with respect to the proposed purchase of land and buildings comprising the Company's Edmonton I, II and III facilities for gross proceeds of approximately CAD$20 million. Due diligence and documentation for this transaction are substantially complete. The Company and the Purchaser are awaiting certain approvals of third parties.
About Radient
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, serving global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its MAP platform to provide premium ingredients that contain a full range of cannabinoid and terpene profiles.
I hope so too! The extraxtors have done well in the past 6 months and RTI was not part of that rally...hopefully they will announce some news and get on par with others in this arena
I hope this is good news as I just loaded up here
VANCOUVER, March 27, 2020 /CNW/ - The following issues have been halted by IIROC:
Company: Radient Technologies Inc.
TSX-Venture Symbol: RTI (All Issues)
Reason: At the Request of the Company Pending News
Halt Time (ET): 9:28 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
Copyright 2020 Canada NewsWire
I was wondering what the hell was going on with no shares traded. You think it is big news?
It’s a supply chain agreement. Looks to me Radient is looking to directly enter the CBD business on a mass scale, 7,500 KG biomass is not that substantial albeit nothing to sneeze at. It is more the alignment and marketing strategies of the Dhaliwal Group that I am interested in. Where do their tentacles reach is the question????
Radient, Allied Dhaliwal to sell CBD
2020-03-18 07:45 ET - News Release
Mr. Denis Taschuk reports
ALLIED CORP. AND RADIENT TECHNOLOGIES INC. ANNOUNCE AGREEMENT TO FACILITATE PREMIUM QUALITY CBD PRODUCTS TO BE SOLD IN CANADA
Allied Corp., an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today's medical issues, and Radient Technologies Inc. have signed a definitive agreement as part of a three-way agreement with the Dhaliwal Group to manage the supply chain, manufacturing and sale of high-quality cannabidiol distillate and isolate.
Under the terms of the agreement, Allied will facilitate the supply and purchase of high-quality CBD distillate and isolate between licensed cultivators and licensed buyers. Industrial hemp biomass will be converted by Radient, for a processing fee, into finished premium quality CBD consumer products, and sold into the Canadian market through a purchasing arrangement made by Dhaliwal. Allied will be responsible for full supply chain management, which involves product moving from legal licensed Canadian industrial hemp farmers, to bonded transport, to Radient's Edmonton I processing facility, through to legally licensed buyers which hold a licence to buy and sell cannabis products in Canada.
The agreement is for an initial 12-month term with an annual option to renew. The three parties expect 7,500 kilograms of biomass to be processed during the first three months of the agreement, with the amount increasing thereafter. Under the terms of the agreement, Radient may also elect to be paid a portion of its processing fees in biomass rather than cash.
"This is a significant milestone achievement for Allied's fifth vertical -- facilitation of the Canadian and European cannabis product supply chain. Retailers are currently facing a challenging environment in receiving quality product. Our executive team, based on our knowledge and experience, is beginning to become a trusted partner in facilitating quality product and we expect many more deals like this to follow," said Calum Hughes, chief executive officer of Allied. "This continues to enable Allied to develop a large reaching sales and distribution network while our Colombian production continues get closer to commercial harvest."
"Radient is very pleased to enter into this agreement with Allied and the Dhaliwal Group," said Radient president and CEO Denis Taschuk. "This agreement will allow us to create the high-quality products that our proprietary continuous-flow extraction and processing technology was intended for. The strength of our manufacturing platform, coupled with Allied's trusted reputation as a responsible and reliable sales partner, enables us to bring premium products to more Canadian consumers, and we look forward to working with both Allied and the Dhaliwal Group."
"This is an exciting milestone for our company, highlighting our efforts to not only secure a foothold in the industry, but also to have a positive impact in the global cannabis industry," said Sukh Dhaliwal, CEO of the Dhaliwal Group. "We are on track for growth and are focused on our strategic corporate plans as we continue to expand globally."
About Radient Technologies Inc.
Radient Technologies is a commercial manufacturer of high-quality cannabinoid-based formulations, ingredients and products. Utilizing a proprietary continuous-flow extraction and processing platform that recovers up to 99 per cent of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety.
From what I’ve read Radient’s doors are wide open and are extracting for Shoppers and hopefully others... GL!
I am confused aswell. I thought Aurora has measure of exclusivity...if memory serves me the Aurora deal was a three year deal. There may have been a provision made if Cronos was first to the table.
I think Radient will do well when it is able to take new customers. I think that Aurora was limiting Radient potential for customers. It will be curious to see how many other deals materialize when the current 3 year deal with acb is done and new facilities are completed.
Can you bottom line me? I read it but am confused. Good for Radient?
Radient big secret...
Anyone know that Cronos is radient costomer? Not I!
Major Customers
For the year ended December 31, 2019, we had three major customers, Ontario Cannabis Store (the cannabis control authority and sole wholesaler and distributor of cannabis in Ontario), Radient Technologies Inc. and MediPharm, sales to each of which are expected to equal or exceed 10% of the Company’s consolidated 2019 net revenues. The Company’s arrangement with MediPharm is described above.”
https://thedeepdive.ca/is-the-medipharm-labs-supply-arrangement-the-source-of-cronos-late-filings/
Slow, steady climb to profitability.
Yes, that was the glaring omission from the press release. But a good steady quality gig nonetheless!
As the Canadian Cannabis industry prepares for Cannabis 2.0 product introductions the Company is well placed to support industry participants through its own product offerings. Within the Company's near-term product pipeline is a range of intermediate, white-label, and formulated offerings to support prospective customers' Cannabis 2.0 initiatives. These offerings range from resins and high purity distillates to stable infusions and emulsions, all of which enable the development of food and beverage, vaping, and personal care products both at large and "craft" scale. The initial intermediate products from this pipeline are expected to launch in February 2020, followed by additional oil and oil capsule products, THC concentrates, and topical products over the subsequent two to three months
https://www.sedar.com/GetFile.do?lang=EN&docClass=8&issuerNo=00035928&issuerType=03&projectNo=03015750&docId=4661998
Wonder what kind of revenue this deal is expected to bring in.
News: $RDDTF Radient Technologies Inc. Announces Proposed Shares for Debt Transaction
EDMONTON, Alberta, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) announces a proposed shares-for-debt transaction in which the Company would issue 192,907 common shares, at a price of CA...
Got this from RDDTF - Radient Technologies Inc. Announces Proposed Shares for Debt Transaction
Guidance of 10X Revenue next quarter! Proof of Tobacco concept. 7 figures!
https://finance.yahoo.com/news/radient-technologies-inc-reports-second-233010482.html
Radient has lost it glow and now appears as dead as this board. Does the news on 10/23 of RDDTF being removed from the OTC market mean it is now a pink sheet stock?
I'm not an aurora holder but, eager to see what happens and what is said tomorrow.
Wow steady climb up. Somebody is accumulating which means somebody knows something.
Definitely buying this earnings price hit! People have no patience. Be in before the revenue run! Volume is gonna be insane when up and running. Here’s to 2020!
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
420
|
Created
|
03/17/17
|
Type
|
Free
|
Moderators |
Radient's patented, proprietary Microwave Assisted Processing or MAP™ technology is based on the selective and localized heating of the moisture present in all natural materials using microwaves as the energy source.
In general, microwaves interact with materials in three ways:
Microwaves do not heat by conduction or convection but rather dielectrically, which in simple terms means microwaves create heat when a material stops or slows the radiation causing it to deposit some of its energy, which is subsequently dissipated as heat. Because microwaves interact directly with the object being heated and because this interaction is related to both the chemical and dielectric properties of the object, it is possible to apply heat (or more precisely, energy) in ways that are not achievable by any other means. Furthermore, every material will absorb microwave energy to a different extent, with individual parts of that material will absorbing the energy differently.
Radient's technological advantage and expertise in selectively depositing microwave energy into different parts of a biomass' complicated chemical system form the core of our extraction advantage.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |